&amp;quot;Real-life&amp;quot; Efficacy and Safety Aspects of 4-Year Omalizumab Treatment for Asthma

Al‐Ahmad, Mona; Arifhodžić, Nermina; Nurkić, Jasmina; Maher, Ahmed; Rodriguez-Bouza, Tito; Al-Ahmed, Nasser; Sadek, Ali; Jusufović, Edin

doi:10.1159/000487482

Cited by 22 publications

(21 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Such important results, referring to placebo-controlled studies, have been also confirmed and expanded by a very large body of real-life investigations carried out worldwide, 80 – 93 which have been systematically reviewed by Abraham and colleagues and by Alhossan and colleagues. 94 , 95 These authors have clearly shown that many patients with severe allergic asthma can be defined as ‘good’ or ‘excellent’ responders to omalizumab with regard to decreases in disease exacerbations, hospital admissions, and overall intake of both oral and inhaled corticosteroids, as well as with regard to improvements in asthma symptoms, pulmonary function, and quality of life.…”

Section: Add-on Therapy Of Severe Asthma With Omalizumabmentioning

confidence: 71%

“… 96 , 97 The relevant benefits obtained in terms of symptom control and lung function, evaluated as significant increases in asthma control test (ACT) score and FEV 1 , respectively, persist and progressively improve during long-term (1–4 years) treatment with omalizumab. 93 Such remarkable improvements including very important clinical, functional, and corticosteroid-sparing effects, associated with a good safety and tolerability profile, have been shown to persist after 7 and even 9 years of anti-IgE therapy. 98 – 100 In addition to corroborating these convincing findings, further data have been obtained by real-life studies.…”

Section: Add-on Therapy Of Severe Asthma With Omalizumabmentioning

confidence: 99%

See 1 more Smart Citation

Omalizumab, the first available antibody for biological treatment of severe asthma: more than a decade of real-life effectiveness

Pelaia

Calabrese

Terracciano

et al. 2018

Ther Adv Respir Dis

114

View full text Add to dashboard Cite

Omalizumab was the first, and for a long time the only available monoclonal antibody for the add-on treatment of severe allergic asthma. In particular, omalizumab selectively targets human immunoglobulin (Ig)E, forming small-size immune complexes that inhibit IgE binding to its high- and low-affinity receptors. Therefore, omalizumab effectively blunts the immune response in atopic asthmatic patients, thus significantly improving the control of asthma symptoms and successfully preventing disease exacerbations. These very positive effects of omalizumab make it possible to drastically decrease both referrals to the emergency room and hospitalizations for asthma exacerbations. Such important therapeutic actions of omalizumab have been documented by several randomized clinical trials, and especially by more than 10 years of real-life experience in daily clinical practice. Omalizumab can also interfere with airway remodelling by inhibiting the activation of IgE receptors located on structural cells such as bronchial epithelial cells and airway smooth muscle cells. Moreover, omalizumab is characterized by a very good safety and tolerability profile. Hence, omalizumab represents a valuable therapeutic option for the add-on biological treatment of severe allergic asthma.

show abstract

Section: Add-on Therapy Of Severe Asthma With Omalizumabmentioning

confidence: 71%

Section: Add-on Therapy Of Severe Asthma With Omalizumabmentioning

confidence: 99%

Omalizumab, the first available antibody for biological treatment of severe asthma: more than a decade of real-life effectiveness

Pelaia

Calabrese

Terracciano

et al. 2018

Ther Adv Respir Dis

114

View full text Add to dashboard Cite

show abstract

“… 6–10 In addition to efficacy, an excellent safety profile has also been confirmed over time, even in fragile patients and under particular conditions, so much so that omalizumab can even be administered to pregnant women. 11 , 12 …”

Section: Introductionmentioning

confidence: 99%

Efficacy and Safety of Omalizumab Treatment Over a 16-Year Follow-Up: When a Clinical Trial Meets Real-Life

Menzella¹,

Fontana²,

Contoli³

et al. 2022

JAA

View full text Add to dashboard Cite

Purpose Treatment of severe asthma has made great strides thanks to rapid progress in understanding immune response and inflammatory pathways. This led to the advent of the first biologic for severe allergic asthma (SAA), omalizumab. Although the long-term efficacy and safety of omalizumab has been confirmed, increasingly longer follow-up data can further reinforce this evidence and potentially provide new ones, for example on any loss of efficacy or the appearance of unexpected side effects. This study reports omalizumab treatment-related outcomes after 16 years of follow-up. Patients and Methods In this real-life retrospective study, an extension of a previous 9-year follow-up study on patients initially recruited in a clinical trial, we enrolled 8 adult patients with SAA followed-up from November 2005 to December 2021. Study subjects were selected based on omalizumab eligibility criteria. Results Exacerbation rate significantly decreased from 3.6 ± 2.1 events in year before index date to 0.1 ± 0.4 after 32 weeks of treatment (p < 0.0001). Mean annual number of mild-to-moderate exacerbations at 16 years was 0.88 compared with 1.8 in the year before the index date and 1.1 at 32 weeks. No hospitalizations were documented during the 16-year follow-up compared to 0.3 hospitalizations/patient in the year before the index date. Respiratory function also progressively and significantly improved. Regarding patient-reported outcomes (PROs), The AQLQ and ACT significantly improved from baseline throughout the follow-up, particularly up to 9 years of follow-up. During the study, an overall reduction in doses of asthma medications was observed, with a significant OCS-sparing effect. Conclusion Our study, the longest clinical follow-up on patients treated with anti-IgE, confirms and amplifies the results of the studies carried out so far, as they are maintained over a very long interval of time without drops in efficacy without any type of side effect.

show abstract

“…Schistosome was one of the parasites that have been found to have protective effects against autoimmune diseases and allergies such as arthritis and asthma ( Osada et al, 2009 ; Janssen et al, 2016 ; Qiu et al, 2017 ). These explorations hold great promise in identifying a new and more specific intervention measure for atopic asthma that does not result in certain side effects, such as increased susceptibility to infection and necrosis, which can be triggered by steroid hormone drugs such as dexamethasone ( Kuprys-Lipinska and Kuna, 2014 ; Al-Ahmad et al, 2018 ; Falk, 2018 ).…”

Section: Introductionmentioning

confidence: 99%

Allergen-Specific Treg Cells Upregulated by Lung-Stage S. japonicum Infection Alleviates Allergic Airway Inflammation

Zhang

Luo

et al. 2021

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Schistosoma japonicum infection showed protective effects against allergic airway inflammation (AAI). However, controversial findings exist especially regarding the timing of the helminth infection and the underlying mechanisms. Most previous studies focused on understanding the preventive effect of S. japonicum infection on asthma (infection before allergen sensitization), whereas the protective effects of S. japonicum infection (allergen sensitization before infection) on asthma were rarely investigated. In this study, we investigated the protective effects of S. japonicum infection on AAI using a mouse model of OVA-induced asthma. To explore how the timing of S. japonicum infection influences its protective effect, the mice were percutaneously infected with cercaria of S. japonicum at either 1 day (infection at lung-stage during AAI) or 14 days before ovalbumin (OVA) challenge (infection at post–lung-stage during AAI). We found that lung-stage S. japonicum infection significantly ameliorated OVA-induced AAI, whereas post–lung-stage infection did not. Mechanistically, lung-stage S. japonicum infection significantly upregulated the frequency of regulatory T cells (Treg cells), especially OVA-specific Treg cells, in lung tissue, which negatively correlated with the level of OVA-specific immunoglobulin E (IgE). Depletion of Treg cells in vivo partially counteracted the protective effect of lung-stage S. japonicum infection on asthma. Furthermore, transcriptomic analysis of lung tissue showed that lung-stage S. japonicum infection during AAI shaped the microenvironment to favor Treg induction. In conclusion, our data showed that lung-stage S. japonicum infection could relieve OVA-induced asthma in a mouse model. The protective effect was mediated by the upregulated OVA-specific Treg cells, which suppressed IgE production. Our results may facilitate the discovery of a novel therapy for AAI.

show abstract

"Real-life" Efficacy and Safety Aspects of 4-Year Omalizumab Treatment for Asthma

Cited by 22 publications

References 27 publications

Omalizumab, the first available antibody for biological treatment of severe asthma: more than a decade of real-life effectiveness

Omalizumab, the first available antibody for biological treatment of severe asthma: more than a decade of real-life effectiveness

Efficacy and Safety of Omalizumab Treatment Over a 16-Year Follow-Up: When a Clinical Trial Meets Real-Life

Allergen-Specific Treg Cells Upregulated by Lung-Stage S. japonicum Infection Alleviates Allergic Airway Inflammation

Contact Info

Product

Resources

About